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therapies are usually non specitic, leading to undesirable
toxieef.fecrton norrna.tcefls. Therefore, an area of active research in
cancerpharmaeologs is the invastieation of the molecular processes
entleal for tumor growth and netatais. that could be peeifieal
targeted in eaneertreatment. En recent sear’. there has been amating
deve.lopments in this area. with the d.i.seove.ry of novel an.t.icancer
t.re.atrri.ents that tareet spee.ific cell sign.ahng pathways, such as Her
ceptin® (Trastuiumah;i, a monoelonal antibody against the Her
tvrosne kinase. and Gice\ cefa 1rnannb \les fatec an inhbtor
at the BCRABL taroitte kinase, ContinuouN alanec’ In c amer
biology and cell ienaling have re ealed new molecular pathwa\ s
that a.re important in the deve.lopmer.t and progress.ion of ean.eer.
The diaevlglveerol signahne patfa ays is one of these.
Diacylglycerol signaling molecules: the PKC
family
Diaeylgiye erol is a major l.ipid se.e.ond. me.t.we.n.ger in the. cell, pro
dueed by the action of phos phol Ipase. entym .s. One of the. m .st
II Ic! _i :-
isiria’e C PR®
. Haute ti a tou serum tlir 1 kniews
transduees diacyleiscerol into a a ide. variety of sie.naisin fluene.ine
ee.i.l prohfhration. diflhre.ntiatiort and s:ur.v.ivil,
The biology of PKC and its role in. disease. has been. extensively
studied twin the phorbtl esters. a nharniacoleeival ru Phor
hal csters are group of ttmural. l)..C1Livt that bc-have a’
mi u iet.ic ; of diaca I ci acer® in the cel.l and as such. they bind, art
ae.ti vate .PKC, The dise.over’ that. a subset of phorhol e.st.e.ri; are-
potent tumor promoters ha.s provided the. first lin.k between PKC arid
e-’ Ifaither studics ha.c resealed other tunctions far PKC. nd
not. Jear that PKC ni only PartictHre’ III tumor promotIon
but also ti tum.or progressort and meta.stasis:
The. ratio. .ale. ot PKC as; a molecular tar et in eane.er therapy is;
further supported ha the fact tha.t PK.C iii so plays a role in ehe.mo
,,_t
,, I
drucs eau’iue eel! deatl’t nv aPontesis. or bs participating in
as sins in Intl sP 011 II as ltust ro hi Itn,n in uiu
transporters.5Thus;, modu.lati.on of .PKC isoforms can serve as an
adjuvant therapy to make cells more se.nsitive. to the. eytotoxie ef
Tee!’ of’ standard c[reniotherapcutie tteatl’ncnts. Iii tact, Inst or the
current eiini5al trials to c’ abtate PKC modulators are esinilning.
thee drugs potentIal adiur out aecnts.
Chemotherapeutic drugs that target PKC
The proiot\ pe of the PKC aetit ator a ith aittitumi;rr activits
bra ostatin I, a natural product that, like the phorhol esters, is a
str Ictur il in dog of di isvlglaeetol fEIgn e I Brsoteatin 1 s tS
ftr5t dseos ered a a result of it’ antileukemie prouerties in vita.
Despite the prilntl’ine nittal aetivit. braostatin i has show II a
s era modest effect as a chemothe-rapeutre druc. \et ertheicss, it
appears to he useful as an adjuvant by enhancing the effdet of van -
ous standard. chemotherapeutie.agen.ts, truch as cisplatin, vincr]ist]ine,
and paclitaxel.’1
in addItIon to brr ‘statrtt I. three toner rtrLIgs that itu et P6K base
been, or lire still h.einc. evaluated in ciineai trIals for treatment at
cancer (for more iriformaton go ll.; http:/../www.el inic.aitrials.gov...’).
These. ineiu.de santingol, staurosporine and. LY3 l 7615, Sanfingol,
a- lipid derivative that binds PKC. has been show ito potentiate the
ca totoxIciiv itrdttced b-v ehemdherapeutir’ dmue like orate ani;i ten
retiitide’- ®rtitineoi appears to niodrtlate other tareetsidditi
to PK.C, howe.ver, there is eLlrrentlv rio active clinical trial to evaluate
th..is. drug in cance.r therapy. The stau.rosporine de.rivatives; fJC®Jt I
and P’K.C4 1 2 are crtrrentlv being tested lti ei.inieal t]rai .
lleemts or in eomt’Inatiou a ith stIttIdath chetroithcmap -\ithouah
stauaosporines.vtis sritIu.tl described as a PKC inhibitor. tee
know that it ea.n. bind other k..inases and it is uncertain whet.h.er the
potentia.l ant.icanee.r effects t;rf the staurosporine derivatives are
due- to moi.lulat..ion r.if PKC exc.l usi ye®-. Final lv, LY 217615’ s
a sete’eti\ e inhibitor of’ P17Cm ath antiatterogene actl.\ its’. Tins
compound it eurrsnils Petite i’stesl ul hse I attn El
in t.hc treatment of liomas and iymphottii..is.
A nove.l approac.h for targ;et.in.g P.KC in cancer therapy i.s the use
of antisense ;(ligor.uc leotides;. .iS’lS352. ‘1 also known as’ ..Affinitak
1 [ I - II I 0 I- 176 isIn’_ 1 1’, ‘a
trails in combi i,iiOtl a
foi-tl’ie treatn’ient of noti-smat.l cell lung caremoma. ‘Unf”orrunatel’.,’.
th’e. trial d.id not sh.ee tiny’ e iinica.i he.ne.’fit®’ .1± it.; im.portant to note
that ‘PKCu ieve.is tv’e.re not measured during the triale therefore, it
still uuknoan whether The neo’ati. I ysilts as vie a
0 a oar Iran or the s’ri.’i’ic rated slectei.
Non-PKC targets of diacylglycerol: chimaerins,
Munc13, PKD and RasGRP
I i1 ,_ I II tP. II 1 ,, I I , 1 1
inc phiirhol esters. and the hrw.wtat ins a-etc thoueltt to be mediated
solely hr PKC. We ;toa dtto’i mat PK.C is rot the sole targcl. as tour
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additional families of diacv Iglveerol targets have been recently dis
covered: the chjmaerins. the Niune proteins, the PKD kinases and
the RasGRP t’amilr Figure 1. One emerging question is whether
these non—PKC receptors could also contribute to careinocenesis
and tumor progression, and therefore. could he potential therapeutic
targets in cancer. Our laboratory at the Cancer Research Center of
l—iawai I is addressine this questioil for RasGRP.
The RasGRP fam I F i a parlicu lark attractive therapeutic target
m cancer because its modulate Ras. a molecule that is implicated
in a sieni lie ant fraction ol human malignancies. Our early work
has contributed to the characteriiation of RasGRP as a high af[in—
hr target for the tumor proinotlilg phorbol esters, and ‘se recentlr
described that oue of the RaNGRP inc mbers RasGR P1 - I uncnons as
a receptor for the phorbol ester’S in epidermal keratinoctes. s hich
are the target cells for tumor promotIon in skin. Studies from
other laboratories has c also linked RasGRP I ss th cancer. Recent
data has idcnti lied RasOR P1 as a noiential leukemia oncocene based
on the results [horn retros ira! inserciona! rnutageuesis
Conclusions
The pG otal iole of diacr ielrccwl pathways in cell proliferation,
differentiation. and apoptosis. provides the rationale for exploiting
diacylglycerol receptors as potential therapeutic targets in cancer,
Treatments that modulate PK(. the major iutracellulardiaeylglyeerol
receptor. have been evaluated in clinical trails for the treatment of
several malignancies. Brr ostatin us the typical PKC modulatorthat
continues to he es aluated as adjus ant ol standai d . h mothrrapeutic
di ties 1 he tart that diacr sIr cerol. phorhol rsters and hrx ostatin I
can also modulate non—PK( diacs IgIr reml tarf rtx rai”r the qties—
non as to the role of the nun—PKc eentors in cancu’. The rerentl\
disros ered propeities of the RasURP as phorhol ester receptor
Ras aeti\ atoi and poteutiil onrocene. make this fan’ik an ‘ittrac—
tis e nos el tat gr t for se Icr t is e i nters r ntu in. Further studies in the
al ea 01 diacs laIr cci ol Si cual ny should pros ide insiehts into the
iole ol caL Ii diicr leIr cerol reLeptor in raneer that mas es entualk
lead to the des clopment of nos el tare tcd therapies ith enhanred
vffeL tis eness and ieducr d tO\ir its
References
I I
Diacyiqlyceroi
IN
;A
— brvostatini
Cl domain
PKC
Ca2 bindina
ohorphorytation
see
PKD
Qi Protein phosphorytation
domain
SH2 GAP domainChimaerlrts
domain
RasGRP Rae 0a2biding
igu 1 Di cylglycerol receptors.
y I P h tr cturr o dacylolycero’. phorbol d y a I I ig t Ii I gr up that are esselal bnar’g to K d on K I y gly 1 po
I aomair resoonfoie for bind rg 10 d’acy’gly rot n I ti tu n to T A 2 Q tetradecanoyl 13 ph orboi acetate PIe o o on ifid SRC a ology
0 I p 0 OPO Ifrosne bndeg Gornain GAP GTP 1w to p r dom I F g n ucle tide excrange facto’ doman
319
LH i::
.;
I
c
H
o 0 (N a
% o
,
CD
CD CD CD
•
CD
—
_
I
z
—
_
I
—
_
a
C?
C) - 0. z 0 CD
o
a
0
0 0
C?
?) CC
C
r?
’
CC
I
C?
)
CD
CC
C
C
C
C
C?
)
CD
CC
T
lv
,
CT
?
r CT
)
CT
)
CD
C
C
’
-
-
,
D
V
CD
-
C
